Teva Pharmaceutical Industries

The 'Zollinger-Ellison Syndrome (Gastrinoma) - Global Clinical Trials Review, 2024' report by ResearchAndMarkets.com offers a comprehensive overview of clinical trials, including trial numbers, enrollment trends, and sponsor types, aiding in strategic decision-making and competitive advantage.

The 'Zollinger-Ellison Syndrome (Gastrinoma) - Global Clinical Trials Review, 2024' report, available on ResearchAndMarkets.com, offers insights into clinical trials for Zollinger-Ellison Syndrome, including trial numbers, enrollment trends, and sponsor details across regions and countries.

Beam Therapeutics reports a patient death in BEAM-101 trial for sickle cell disease, unrelated to the therapy. Sana Biotechnology refocuses on autoimmune assets, reducing workforce. Ring Therapeutics expands in Singapore with new deals. Drug regulators criticized for ignoring forced labor in supply chains. OSE Therapeutics' IL-7 therapy shows positive results in ulcerative colitis trial. Japan's PMDA opens second overseas office in Washington.

The global necrotizing fasciitis treatment market is expected to grow from USD 2.9 billion in 2024 to USD 4.5 billion by the forecast period's end, driven by personalized therapies, targeted antimicrobial treatments, and advanced imaging technologies. Key players are innovating with novel antibiotics, biologics, and less invasive surgical methods, while strategic collaborations accelerate breakthroughs. Recent developments include GSK's acquisition of Elsie Biotechnologies and Merck's partnership with Mycenax Biotech.

Organon announced FDA acceptance of its aBLA for HLX14, a biosimilar of Amgen’s Prolia®/Xgeva® (denosumab), licensed from Shanghai Henlius Biotech. Teva also announced FDA and EMA acceptance of its Prolia® biosimilar TVB-009P. These join Celltrion, Fresenius Kabi, and Samsung Bioepis’s denosumab biosimilar applications awaiting FDA approval. Litigations between Amgen and Celltrion, Samsung Bioepis, and Fresenius Kabi are ongoing. Sandoz’s Jubbonti®/Wyost® (denosumab-bddz) was FDA-approved as interchangeable with Prolia®/Xgeva®, with a U.S. market entry date by May 31, 2025, or earlier under certain circumstances.

Olanzapine long-acting injectable (LAI) TEV-‘749 / mdc-TJK showed significant improvement in social functioning and quality of life for schizophrenia patients, with no incidents of post-injection delirium/sedation syndrome (PDSS). Real-world analyses also revealed high use and adherence rates for UZEDY® (risperidone) LAI.

Goodwin's 1,600 lawyers in the U.S., Europe, and Asia provide complex transactions, high-stakes litigation, and advisory services in technology, life sciences, real estate, private equity, and financial industries, distinguishing themselves with deep experience in both innovation and investment.

Teva's Phase III SOLARIS trial of TEV-'749 in schizophrenia patients showed significant improvements in social functioning and quality of life. The subcutaneous long-acting injectable met primary endpoint in PANSS total score, with no PDSS observed.

Teva Pharmaceuticals announces positive Phase 3 SOLARIS trial results for TEV-‘749, a once-monthly subcutaneous olanzapine formulation for schizophrenia, showing significant improvements in social functioning and quality of life with a safe profile.

Teva presented positive Phase 3 SOLARIS trial results for Olanzapine LAI, showing significant improvements in social functioning and quality of life in schizophrenia patients, with no PDSS events. Real-world data on UZEDY revealed high adherence rates among socially vulnerable schizophrenia patients.